Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28784026 | 0.87 | ALDH1A1 (0.69) | ALDH1A1LMNAGAAKMT2APOLB | |
| SCHEMBL3830424 | 0.86 | POLB (0.80) | ALDH1A1LMNAGAAPOLBPKM | |
| SCHEMBL735657 | 0.86 | POLB (0.80) | ALDH1A1LMNAGAAPOLBPKM | |
| SCHEMBL7122592 | 0.86 | POLB (0.80) | ALDH1A1LMNAGAAPOLBPKM | |
| SCHEMBL14590548 | 0.86 | ALDH1A1 (0.67) | ALDH1A1LMNAGAAKMT2APOLB | |
| SCHEMBL6744907 | 0.84 | KMT2A (0.70) | ALDH1A1LMNAGAAKMT2APOLB | |
| SCHEMBL1870003 | 0.84 | PKM (0.55) | ALDH1A1LMNAGAAKMT2APOLB | |
| SCHEMBL20502397 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAGAAKMT2APOLB | |
| SCHEMBL10726980 | 0.84 | LMNA (0.81) | ALDH1A1LMNAGAAKMT2ACASP6 | |
| SCHEMBL5915285 | 0.84 | LMNA (0.70) | ALDH1A1LMNAKMT2APOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | claimed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | claimed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| CN-104693193-B | Aryl methoxy isoindoline derivative and composition and their application method including it | 细胞基因公司 | 2018-09-18 | — | — | CN | disclosed |
| WO-2013103973-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | disclosed |
| US-6696418-B1 | ANIMAL GROWTH REGULATORS SUCH AS 6-AMINO-2-(2-((1-BENZENE SULFONYL-PIPERIDINE-4-CARBONYL)-AMINO)-3-(1H-INDOL-3-YL)-PROPIONYLAMINO) -HEXANOIC ACID TERT-BUTYL ESTER, ADMINISTERED TO MODULATE CELL DIFFERENTIATION | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | disclosed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | ALDH1A1 3407/4885LMNA 2997/4885GAA 2592/4885 |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | ALDH1A1 3284/4885LMNA 2952/4885GAA 2514/4885 |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | ALDH1A1 3284/4885LMNA 2952/4885GAA 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.